Discontinued drugs in 2008: endocrine and metabolic (Q38449224)

3 September 2017

Discontinued drugs in 2008: endocrine and metabolic (English)

1 reference

3 September 2017

Jerry R Colca

1

1 reference

PubMed ID

19678796

3 September 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Investigational Drugs

3 September 2017

1 reference

3 September 2017

18

1 reference

3 September 2017

9

1 reference

3 September 2017

1243-1255

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

3 September 2017

1 reference

Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

The endocannabinoid system as an emerging target of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Impairments in endocannabinoid signaling and depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Squalene synthase inhibition: a novel target for the management of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

Treatment with a cholesterol absorption inhibitor (FM-VP4) reduces body mass and adipose accumulation in developing and pre-obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903132673

10.1517/13543780903132673

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

19678796